昌吉治阴道紧缩医院哪个好昌吉男科有哪些医院,昌吉术后的包皮,昌吉精液检查怎么检查,昌吉早泄手术费用多少钱,昌吉怎么可以让男人持久,昌吉包皮手术大概需多少钱,昌吉无痛人流需要多少钱大概多少钱

Today we honor Alex Trebek. For over three decades he brought integrity, humor and intelligence to his duties as host of Jeopardy! He will be in our hearts forever.Thank you, Alex. Love from us all. ?? pic.twitter.com/w8abYY8SX5— Jeopardy! (@Jeopardy) November 10, 2020 277

Those in charge of the race for a COVID-19 vaccine are trying to keep the process transparent.“Those checks aren’t just critical to the development of a safe and effective vaccine, although they are, they are also essential to maintaining and inspiring the public trust,” said Ana Mari Cauce, President of the University of Washington.Johns Hopkins and the University of Washington hosted a virtual symposium. Dr Anthony Fauci took part, as did the head of Operation Warp Speed, the public and private partnership overseeing COVID vaccine therapies.He's vowed to resign if political pressure impacts a vaccine being safe and effective.“We expect them to read that or have a first look at their efficacy outcome within the next several weeks,” said Dr. Moncef Slaoui, Chief Advisor for Operation Warp Speed. “Nobody can really say when, but the expectation would be that this would happen between the month of November and December.”There are detailed plans and protocols at some 25 manufacturing sites across the U.S.Independent experts with decades of experience in Ebola, Zika and HIV gave perspective on COVID-19 vaccine trials.“We use 30,000 and if you actually calculate how many is needed for efficacy, most companies would do it around 15,000, but we fortunately have the funding to be able to do larger trials,” said Dr. Larry Corey, a vaccine and infectious disease expert.The experts promised that phase-3 trial data would be publicly vetted during a broadcasted advisory committee meeting.You can see the full symposium on Johns Hopkins University's YouTube page right now. 1592

This holiday season, a word of caution from charity experts. If you're able to donate, make sure you do your homework, and make a plan for your money so that it supports a worthy cause.Court documents from September detail a four-state investigation that shut down a sham charity, which, according to investigators, bilked consumers out of millions. They claimed to use donations to help homeless veterans, breast cancer survivors, and disabled law enforcement. But the real people in need got next to nothing."The fraudsters out there are relying on your generosity your good wishes, the fact that you can’t say no when somebody says something like veterans or children or breast cancer- they want to tug on those heartstrings," said Yael Fuchs, President of the National Association of State Charity Officials (NASCO). "NASCO was formed so that state charity regulators can talk to each other, so that we can learn from each other, so that we can share tips and make sure that we are coordinating our enforcement efforts.”They often work together to take down the bad guys. And when they're not doing that, they're proactively following fundraising drives. “Do we see exorbitant amounts of money going to professional fundraisers- do we see big upticks in the salaries that the leaders of the charity are making,” Fuchs said.They look for ways in which people are being taken advantage of. So, how do you know who's good and who's not? Enter organizations like Charity Navigator. “We’re a database with all of the registered nonprofits in the United States,” said Michael Thatcher, President, and CEO of Charity Navigator. Thatcher says the company has grown to be the largest independent evaluator of nonprofits in the country. Basically, they give you all the tools you need to make the right decisions when it comes to donations.“Never charge the donor for access to the information and never charge the charities to be evaluated so you eliminate any potential conflict of interest,” Thatcher said If you're looking to give this year, he recommends focusing on how the organization is run, how they're making a difference in the world. Review their financial data, and ask questions - lots of questions. "How have they pivoted around COVID and how have they stayed true to their mission and also stayed in business?" Thatcher added.NASCO recommends you do extensive research. And be specific about the "cause" you want to support. “Where is my money going- how will it be used? What we always want people to remember is you don’t want to give to a buzzword you’re not just giving to a cause you’re giving to a particular charity so you want to be able to trust that charity to understand what their programs are.” The need will be big this year. And donations will be unpredictable. So, experts also say, make a plan, talk to your family, and give with intent so that your donation goes where it's supposed to. 2923

THOUSAND OAKS, Calif. (AP) -- A survivor of the mass shooting at a Southern California bar was also at the Las Vegas music festival that ended in a massacre last year.Dani Merrill says she's upset that such bloodshed has now come to her hometown.Merrill joined hundreds of people at a vigil Thursday night to mourn those killed at the Borderline bar in Thousand Oaks.RELATED: 13 dead in mass shooting at Thousand Oaks barMerrill says she escaped when the shooting began by running out onto the bar's loading dock.Thousand Oaks acting Mayor Rob McCoy told the crowd the city is hurting but will heal.RELATED: Lawmakers respond to Thousand Oaks mass shooting 674

Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published Tuesday. Adding to the concern: It is likely that the speed of increasing resistance will outpace the slow drug development process.As of May, a total of 51 antibiotics and 11 biologicals -- medical products often made from natural sources -- are being developed, the new report said."The idea is that biologicals could replace use of antibiotics, which could help in overcoming the resistance problem," Peter Beyer, an author of the report and senior adviser to the WHO's Department of Essential Medicines and Health Products, wrote in an email.Seemingly, this large number of potential new drugs should suffice, yet it is not nearly enough.First, just 33 of the antibiotics in the pipeline target priority pathogens. This year, the WHO published a list of a dozen "priority pathogens": 12 separate families of antibiotic-resistant bacteria that pose the greatest threat to human health.Among the priority pathogens is a drug-resistant tuberculosis, which kills about 250,000 people around the world each year, and a variety of multidrug resistant strains -- Acinetobacter, Pseudomonas and various Enterobacteriaceae -- which are responsible for infections in hospitals and nursing homes and among patients whose care requires ventilators and catheters.Of the 33 potential medicines for treating priority bug infections, only eight are innovative treatments. The other 25 are simple modifications of existing families of antibiotics. At best, then, the 25 will serve as short-term solutions since it is expected bacteria will quickly adapt to and resist these new (though somewhat familiar) drugs, according to the WHO."It is difficult to speculate why companies develop specific new medicines," Beyer noted. "But in general many new treatments do not necessarily constitute advances over existing treatments."TB infections require a combination of at least three antibiotics, according to the new report, yet only seven of the new TB medicines are even in clinical trials. Soon, there will be a serious lack of treatment options for this infection, the report warns.The same is true for gram-negative pathogens, which can cause severe, often deadly infections typically in hospitals and nursing homes.Gram-negative bacteria have more complex cell walls than gram-positive, explained Beyer. "In a nutshell, it is more complex to develop a novel antibiotic that can penetrate the complex gram-negative cell wall and stay inside the bacterium," he wrote.Finally, the WHO sees too few oral antibiotics being developed. These are necessary "to target the critical priority pathogens (and) be accessible in low- and middle-income countries," Beyer noted.To address the problem of developing new antibiotics, the WHO and the Drugs for Neglected Diseases Initiative set up the Global Antibiotic Research and Development Partnership. However, new drugs alone cannot combat the threat of antimicrobial resistance. The WHO is also working to improve infection prevention and control while developing guidance for the responsible use of antibiotics."Always seek medical advice before taking antibiotics and then always follow the advice of the health-care professional," Beyer noted.The new report is a "fantastic (and very useful!) summary" of the antibiotic situation, wrote Bill Hanage, an associate professor of epidemiology at Harvard T.H. Chan School of Public Health, in an email. Hanage, who has also published studies of antibiotic resistance, was not involved in the new report.Although the risk of getting a completely resistant infection is low in the United States, about 2 million people each year become infected with "resistant enough" bacteria that are harder to treat, Hanage said. And every year, more than 20,000 people die of these infections."More resistant infections don't just mean you or someone you care about is more likely to die from one, they also mean healthcare will get even more expensive," Hanage said. "Many of the procedures we take for granted in medicine, from cancer treatments to surgeries, depend on our ability to handle infections that happen in the course of treatment."The number of new drugs in development is simply not enough, he said."The great majority will not make it into the hands of doctors or your treatment," Hanage wrote. "As the report states, for drugs to be used in humans they have to pass 3 hurdles, the phase 1, 2 and 3 trials. Drugs entering that pipeline have just a 14% chance of getting all the way through to be used in humans." 4676